Clinical Trial: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT06915025) titled 'Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer' on April 01.

Brief Summary: This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Study Start Date: April 21

Study Type: INTERVENTIONAL

Condition: Epithelial Ovarian Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma

Intervention: DRUG: IMNN-001 (IL-12 Plasmid Formul...